Denmark LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has let a considerable number of employees go, closed research centres and restructured its R&D team. While LEO’s financials look promising…
Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…
Greece Nicos Ragoussis explains how he steered the Greek affiliate of Danish dermatology specialist LEO Pharma through the unprecedented challenges of the government-debt crisis era, the ongoing market access hurdles that still remain, and why he is highly optimistic about future business prospects. The hard times are behind us and…
Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…
Egypt Building on a stellar career in pharma and medtech both in Egypt and internationally, Ahmed Ezz El-Din now serves as CEO of Cleopatra Hospitals Group, Egypt’s largest private hospital provider. Dr Ezz El-Din explains why implementing an organisational and management structure based on that of the pharma industry helps Cleopatra…
Egypt While universal health insurance is the talk of the town in Egypt today, private healthcare groups – serving up to 40 percent of the population in both the insurance and out-of-pocket markets – still have an important role to play. This role covers both providing high quality care to their…
Global GSK has separated itself from its consumer healthcare business, newly named Haleon, home to brands such as Sensodyne and Advil. Now what? After underperforming in recent years, a few clinical trials fails and a resulting push for change from its investors, the breakup with its consumer healthcare arm was long-announced…
India The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related to COVID-19. Local companies performed well thanks to strong domestic demand and several, such as the five listed below, grew…
Denmark Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years, LEO is now on the lookout for a replacement with capital market experience and the ability to steer the firm…
Denmark Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided between their shareholders and the foundations themselves, with funds then channelled into academia and biotech start-ups. Here, a variety of…
USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…
USA With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the novel coronavirus. However, even as great strides have been made on that front, companies have to continue delivering their existing…
See our Cookie Privacy Policy Here